Unaudited Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 76,353	$ 24,194
Marketable securities	40,725	27,802
Prepaid expenses and other assets	5,122	2,596
Total current assets	122,200	54,592
Property and equipment, net	7,590	8,628
Right of use assets – operating leases	3,047	4,822
Restricted cash	30	0
Deferred financing costs	146	4,111
Total assets	133,013	72,153
Current liabilities:
Accounts payable	2,487	1,728
Accrued expenses	9,614	10,361
Deferred revenue	1,416	2,459
Operating lease liabilities	2,486	3,437
Finance lease liabilities	1,215	1,162
Other current liabilities	755	523
Total current liabilities	17,973	19,670
Deferred revenue	45,000	45,000
Convertible promissory note	0	33,717
Derivative liability	0	5,739
Operating lease liabilities	920	976
Finance lease liabilities	606	872
Other long-term liabilities	1,809	1,041
Total liabilities	66,308	107,015
Commitments and contingencies (Note 5)
Convertible preferred stock	0	107,808
Stockholders’ equity (deficit):
Common stock $0.001 par value, 350,000,000 shares authorized, 40,269,576 and 2,217,737 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	40	2
Additional paid-in capital	269,141	1,197
Accumulated other comprehensive income (loss)	265	(41)
Accumulated deficit	(202,741)	(158,223)
Total Carisma Therapeutics Inc. stockholders’ equity (deficit)	66,705	(157,065)
Noncontrolling interests	0	14,395
Total stockholders’ equity (deficit)	66,705	(142,670)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$ 133,013	$ 72,153